ID | 55587 |
JaLCDOI | |
フルテキストURL | |
著者 |
Honda, Yoshihiro
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Takigawa, Nagio
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Ichihara, Eiki
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Ninomiya, Takashi
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Kubo, Toshio
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Ochi, Nobuaki
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Yasugi, Masayuki
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Murakami, Toshi
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Yamane, Hiromichi
General Internal Medicine 4, Kawasaki Medical School
Tanimoto, Mitsune
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Kiura, Katsuyuki
Department of Allergy and Respiratory Medicine, Okayama University Hospital
|
抄録 | (−)-Epigallocatechin-3-gallate (EGCG) has been shown to bind to several receptors including epidermal growth factor receptor (EGFR). EGFR tyrosine kinase inhibitors and anaplastic lymphoma kinase (ALK) inhibitors are effective for non-small cell lung cancers harboring activating EGFR mutations and ALK or c-ros oncogene 1 (ROS1) fusion genes, respectively. We investigated the effects of EGCG on EGFR- or fusion gene-driven lung cancer cells such as PC-9, RPC-9, H1975, H2228 and HCC78. The five cell lines had similar sensitivity to EGCG. Phosphorylated (p)EGFR, pAkt and pErk in PC-9, RPC-9 and H1975 cells were suppressed by EGCG (50 or 100 μM). EGCG also inhibited pALK in H2228, pROS1 in HCC78, and pErk and pAkt in both cell lines. All the xenograft tumors established using the 5 cell lines in EGCG-treated groups were significantly smaller than the tumors in the vehicle-treated groups. The numbers of tumor blood vessels of xenograft tissues in EGCG-treated mice were significantly lower than those in vehicle-treated mice. In conclusion, EGCG may be effective for EGFR-driven lung tumors irrespective of the presence of T790M, and for ALK or ROS1 fusion gene-driven lung tumors.
|
キーワード | epigallocatechin-3-gallate
lung cancer
EGFR
ALK
ROS1
|
Amo Type | Original Article
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2017-12
|
巻 | 71巻
|
号 | 6号
|
出版者 | Okayama University Medical School
|
開始ページ | 505
|
終了ページ | 512
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | CopyrightⒸ 2017 by Okayama University Medical School
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID |